Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide vs Chemotherapy in AR+ Metastatic TNBC
NCT03055312Phase 3Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bicalutamide in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Started Dec 2016; status: terminated.
02
Drugs
bicalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03055312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055312.